



Amendments to the Claims

Please cancel Claim 2 and Claim 6.

Please amend Claims 1, 3-5, 7, 8 and 11.

Please add new Claims 12-20.

The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently Amended) A method of treating TNF α -mediated joint ankylosis in a human comprising administering to the human an effective TNF-inhibiting TNF α -inhibiting amount of an anti-TNF anti-TNF α chimeric antibody, wherein said anti-TNF anti-TNF α chimeric antibody competitively inhibits binding of TNF human TNF α to anti-TNF α chimeric monoclonal antibody cA2.
2. (Canceled)
3. (Currently Amended) A method of treating TNF α -mediated joint ankylosis in a human comprising administering to the human an effective TNF-inhibiting TNF α -inhibiting amount of chimeric anti-TNF anti-TNF α chimeric monoclonal antibody cA2.
4. (Currently Amended) A method for treating TNF α -mediated joint ankylosis in a human comprising administering to the human at least one anti-TNF α chimeric monoclonal antibody cA2, or a TNF binding an antigen-binding fragment thereof.
5. (Currently Amended) A method of treating TNF α -mediated joint ankylosis in a human comprising administering to the human an effective TNF-inhibiting TNF α -inhibiting amount of an anti-TNF anti-TNF α chimeric antibody, wherein said anti-TNF anti-TNF α chimeric antibody comprises an IgG1 constant region and competitively inhibits binding of TNF human TNF α to anti-TNF α chimeric monoclonal antibody cA2.

6. (Canceled)
7. (Currently Amended) A method of treating TNF α -mediated joint ankylosis in a human comprising administering to the human an effective TNF-inhibiting TNF α -inhibiting amount of an anti-TNF anti-TNF α chimeric antibody, wherein said anti-TNF anti-TNF α chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.
8. (Currently Amended) A method of treating TNF α -mediated joint ankylosis in a human comprising administering to the human an effective TNF-inhibiting TNF α -inhibiting amount of an anti-TNF anti-TNF α chimeric antibody, wherein said anti-TNF anti-TNF α chimeric antibody comprises an IgG1 human constant region and a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.
9. (Original) The method of Claim 7 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.: 4.
10. (Original) The method of Claim 8 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.: 4.
11. (Currently Amended) A method of treating TNF α -mediated joint ankylosis in a human comprising administering to the human an effective TNF-inhibiting TNF α -inhibiting amount of an anti-TNF anti-TNF α chimeric antibody, wherein said anti-TNF anti-TNF α chimeric antibody has epitopic specificity identical to monoclonal antibody cA2.

12. (New) The method of Claim 1 wherein said anti-TNF α antibody binds with high affinity to a neutralizing epitope of human TNF α .
13. (New) The method of Claim 1 wherein said anti-TNF α antibody binds to a neutralizing epitope of human TNF α *in vivo* with an affinity of at least 1×10^8 liter/mole, measured as an association constant (Ka), as determined by Scatchard analysis.
14. (New) The method of Claim 1 wherein said anti-TNF α antibody is administered to the human by means of parenteral administration.
15. (New) The method of Claim 1 wherein said anti-TNF α antibody is administered to the human by means of intravenous administration.
16. (New) The method of Claim 1 wherein said anti-TNF α antibody is administered to the human by means of subcutaneous administration or intramuscular administration.
17. (New) The method of Claim 1 wherein said anti-TNF α antibody is administered to the human orally.
18. (New) The method of Claim 1 wherein said TNF α -inhibiting amount of the anti-TNF α antibody comprises a single or divided dose of about 0.1 - 50 mg/kg.
19. (New) The method of Claim 18 wherein said single or divided dose is selected from the group consisting of: about a 0.1 - 1 mg/kg dose, about a 1.0 - 5 mg/kg dose, about a 5 - 10 mg/kg dose and about a 10 - 20 mg/kg dose.
20. (New) The method of Claim 1 further comprising administering to the human an effective amount of a therapeutic agent selected from the group consisting of: radiotherapeutics, cytotoxic drugs, monoclonal antibodies, chimeric antibodies, antibody fragments, antibody regions, lymphokines, cytokines, hemopoietic growth factors and

immunoglobulins.